Healthcare Q3 Results Preview - Pharma To See Strong Ebitda Growth Aided By U.S. Markets: Prabhudas Lilladher

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Prabhudas Lilladher Report.We expect pharmaceuticals companies under our coverage to report another strong quarter with Ebitda growth of 19% YoY (flat QoQ) mainly aided by - new launches (gRevlimid, gSpiriva, etc) in U.S. market,steady domestic business and higher margins. We expect the quarter to continue seeing easing of cost pressures which will thereby aid margins YoY. The companies have witnessed slow pick up in flu season which will be offset by steady base business and new launches. On domestic formulation business; volumes offtake in acute and trade generic segments are likely to recover while benefit of price hike in National List of Essential Medicines portfolio and steady growth in chronic portfolio will be seen in few domestic focused companies. Our top picks remain Sun Pharmaceuticals Industries Ltd., JB Chemicals and Pharmaceuticals Ltd., Eris Lifesciences Ltd. and Torrent Pharmaceuticals Ltd..Hospitals: Steady growth despite weak season despite Q3 being seasonally weak quarter, we forecast hospital companies to deliver healthy YoY growth in Q3 FY24 aided by higher average revenue per occupied bed and steady occupancy. However, on sequential basis we anticipate 100-400 basis points decline in occupancy impacted by festive season. Further state elections in Telangana and cyclone impact in Chennai have also impacted occupancy for Andhra Pradesh, Telangana and Chennai based units. This will impact growth for Apollo Hospitals Enterprises Ltd. and Krishna Institute of Medical Sciences Ltd. hospital business given their presence. We forsee ARPOB to continue to remain higher on YoY basis. Overall, we expect +16% YoY growth (down 5% QoQ) in post Indian Accounting Standard Ebitda (excluding of Rs 1.67 billion loss in Apollo 24*7, Ebitda growth expected at +12.3% YoY) in Q3 for our coverage universe. We remain structurally positive in the hospitals space and expect momentum to continue with- improvement in occupancy,better case- payor mix andnew capacity additions. Our top picks in the sector are Max Healthcare Institute Ltd., Jupiter Lifeline Hospitals Ltd. and Fortis Healthcare Ltd..Click on the attachment to read the full report:.Chemical Sector Q3 Results Preview - Revival Likely But Timing Is Uncertain: Nirmal Bang.DISCLAIMERThis report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Healthcare Q3 Results Preview - Pharma To See Strong Ebitda Growth Aided By U.S. Markets: Prabhudas Lilladher

Hospitals to see steady growth despite weak season

NDTV Profit

NDTV Profit

Follow Us

DOWNLOAD THE APP

Healthcare Q3 Results Preview - Pharma To See Strong Ebitda Growth Aided By U.S. Markets: Prabhudas Lilladher

Hospitals to see steady growth despite weak season

Choose a plan

Follow Us

DOWNLOAD THE APP